EGFR first- and second-generation TKIs-there is still place for them in EGFR-mutant NSCLC patients.

EGFR first- and second-generation TKIs-there is still place for them in EGFR-mutant NSCLC patients.
复制标题

DOI:
10.21037/tcr.2018.10.06
复制
发表时间:
2019-01
影响因子:
0.9
通讯作者:
Rosell R
Rosell R
中科院分区:
医学4区
文献类型:
--
作者:
Karachaliou N;Fernandez-Bruno M;Bracht JWP;Rosell R

文献摘要

参考文献

被引文献

相似文献

表皮生长因子受体(EGFR)作为分子靶点的发现已经从根本上改变了转移性非小细胞肺癌(NSCLC)的治疗,从标准化疗到个性化靶向治疗。目前,第一代、第二代和第三代EGFR酪氨酸激酶抑制剂(TKIs)可用于治疗EGFR突变型NSCLC患者。本文将重点介绍第一代和第二代EGFR TKIs的临床发展。我们将强调一些要点,如EGFR TKIs之间的正面比较,它们对脑转移瘤的活性,耐药机制,以及它们与抗血管生成化合物,其他靶向治疗或免疫治疗的联合。第一代和第二代EGFR TKIs在早期EGFR突变NSCLC中的疗效也将最终进行综述。
Identification of epidermal growth factor receptor (EGFR) as a molecular target has radically changed the treatment of metastatic non-small cell lung cancer (NSCLC) from standard chemotherapy to personalized, targeted therapy. First-, second- and third-generation EGFR tyrosine kinase inhibitors (TKIs) are now available for the treatment of EGFR-mutant NSCLC patients. This review will focus on the clinical development of first- and second-generation EGFR TKIs. We will emphasize on essential points like the head-to-head comparison among EGFR TKIs, their activity on brain metastases, mechanisms of resistance, as well as their combination with anti-angiogenic compounds, other targeted therapies, or immunotherapy. The efficacy of first- and second-generation EGFR TKIs in early-stage EGFR-mutant NSCLC will be also finally reviewed.
DOI: 10.1038/ng.3990
发表时间: 2017-12
期刊: Nature genetics
影响因子: 30.8
作者:
Blakely CM;Watkins TBK;Wu W;Gini B;Chabon JJ;McCoach CE;McGranahan N;Wilson GA;Birkbak NJ;Olivas VR;Rotow J;Maynard A;Wang V;Gubens MA;Banks KC;Lanman RB;Caulin AF;St John J;Cordero AR;Giannikopoulos P;Simmons AD;Mack PC;Gandara DR;Husain H;Doebele RC;Riess JW;Diehn M;Swanton C;Bivona TG
通讯作者: Bivona TG
DOI: 10.1016/j.lungcan.2013.08.002
发表时间: 2013-11-01
期刊: LUNG CANCER
影响因子: 5.3
作者:
Ciuleanu, T.;Tsai, C. -M.;Thatcher, N.
通讯作者: Thatcher, N.
EGFR阻断通过Notch3依赖性信号传导富集了肺癌干细胞。
DOI: 10.1158/0008-5472.can-13-3724
发表时间: 2014-10-01
期刊: Cancer research
影响因子: 11.2
作者:
Arasada RR;Amann JM;Rahman MA;Huppert SS;Carbone DP
通讯作者: Carbone DP
DOI: 10.1016/j.rmcr.2017.01.016
发表时间: 2017
影响因子: 1.1
作者:
Bartholomew C;Eastlake L;Dunn P;Yiannakis D
通讯作者: Yiannakis D
DOI: 10.1371/journal.pone.0089518
发表时间: 2014-02-25
期刊: PLOS ONE
影响因子: 3.7
作者:
Benlloch, Susana;Luisa Botero, Maria;Taron, Miquel
通讯作者: Taron, Miquel